亚洲欧美中文日韩天堂,久久精品—区二区三区无码伊人色

首頁> 產(chǎn)品列表> 細(xì)胞信號傳導(dǎo) JAK/STAT信號通路>

一甲基澳瑞他汀 F

NMR下載 COA and HPLC MSDS下載
names：
Monomethyl Auristatin F
CAS號：
745017-94-1
MDL Number： MFCD25976742
MF(分子式)： C39H65N5O8 MW(分子量)： 731.96
EINECS:Not available Reaxys Number:Not available
Pubchem ID:10395173 Brand:BIOFOUNT

一甲基澳瑞他汀 F(745017-94-1,Monomethyl Auristatin F,MMAF)是一種有效的微管蛋白聚合抑制劑，一甲基澳瑞他汀 F具有腫瘤抗性。MMAF (Monomethylauristatin F) 廣泛用作抗體偶聯(lián)藥物 (ADCs) 的細(xì)胞毒性成分，如 Vorsetuzumab mafodotin 和 SGN-CD19A。

貨品編碼	規(guī)格	純度	價(jià)格 (￥)	現(xiàn)價(jià)(￥)	特價(jià)(￥)	庫存描述	數(shù)量	總計(jì) (￥)
HCC336667-5mg	5mg	97%	￥ 2593.50	￥ 2593.50		4-7周	- +	￥ 0.00

大包裝詢價(jià) 提供各種包裝，敬請垂詢
收藏商品商品點(diǎn)評加入購物車立即購買

快速詢價(jià)

收起

你想詢價(jià)的產(chǎn)品

*產(chǎn)品名稱：

CAS號：

產(chǎn)品編號：

需求描述：

請準(zhǔn)確填寫您的聯(lián)系方式，以便為您提供最好的服務(wù)。

*公司名稱：

*電子郵箱：

聯(lián)系人：

*電話：

*驗(yàn)證碼：

詢價(jià)

中文別名	一甲基澳瑞他汀 F(745017-94-1,Monomethyl Auristatin F,MMAF),一甲基瑞奧西汀F,甲基澳瑞他汀F
英文別名	Monomethyl Auristatin F,745017-94-1,MMAF
CAS號	745017-94-1
Inchi	InChI=1S/C39H65N5O8/c1-12-25(6)34(43(9)38(48)33(24(4)5)42-37(47)32(40-8)23(2)3)30(51-10)22-31(45)44-20-16-19-29(44)35(52-11)26(7)36(46)41-28(39(49)50)21-27-17-14-13-15-18-27/h13-15,17-18,23-26,28-30,32-35,40H,12,16,19-22H2,1-11H3,(H,41,46)(H,42,47)(H,49,50)/t25-,26+,28-,29-,30+,32-,33-,34-,35+/m0/s1
InchiKey	MFRNYXJJRJQHNW-DEMKXPNLSA-N
分子式 Formula	C39H65N5O8
分子量 Molecular Weight	731.96
溶解度Solubility	DMF (Slightly), DMSO (Slightly), Methanol (Slightly), Water (Slightly)
性狀	白色固體粉末
儲藏條件 Storage conditions	干燥，避光，短期（幾天至幾周）處于0-4°C，長期（幾個(gè)月至幾年）處于-20°C。

一甲基澳瑞他汀 F(745017-94-1,Monomethyl Auristatin F,MMAF) 實(shí)驗(yàn)注意事項(xiàng)：
1.實(shí)驗(yàn)前需戴好防護(hù)眼鏡，穿戴防護(hù)服和口罩，佩戴手套，避免與皮膚接觸。
2.實(shí)驗(yàn)過程中如遇到有毒或者刺激性物質(zhì)及有害物質(zhì)產(chǎn)生，必要時(shí)實(shí)驗(yàn)操作需要手套箱內(nèi)完成以免對實(shí)驗(yàn)人員造成傷害
3.實(shí)驗(yàn)后產(chǎn)生的廢棄物需分類存儲，并交于專業(yè)生物廢氣物處理公司處理，以免造成環(huán)境污染

Monomethyl Auristatin F(745017-94-1,MMAF) Experimental considerations:
1. Wear protective glasses, protective clothing and masks, gloves, and avoid contact with the skin during the experiment.
2. The waste generated after the experiment needs to be stored separately, and handed over to a professional biological waste gas treatment company to avoid environmental pollution.

Tag:一甲基澳瑞他汀 F(745017-94-1,Monomethyl Auristatin F,MMAF),一甲基澳瑞他汀 F試劑,一甲基澳瑞他汀 F抑制劑,一甲基澳瑞他汀 F的作用,一甲基澳瑞他汀 F的合成,一甲基澳瑞他汀 F的純度,一甲基澳瑞他汀 F的生產(chǎn),一甲基澳瑞他汀 F的MSDS

產(chǎn)品說明	一甲基澳瑞他汀 F(745017-94-1,Monomethyl Auristatin F,MMAF)是一種有效的微管蛋白聚合抑制劑，一甲基澳瑞他汀 F具有腫瘤抗性。
Introduction	Monomethyl Auristatin F (745017-94-1, 一甲基澳瑞他汀 F, MMAF) is a potent inhibitor of tubulin polymerization. Monomethyl Auristatin F has tumor resistance.
Application1	Monomethyl Auristatin F (745017-94-1, 一甲基澳瑞他汀 F, MMAF) can be used as a reference substance for drug impurities and reagents，only for research.
Application2
Application3

Monomethyl auristatin F (MMAF) is a synthetic antineoplastic agent. It is part of some experimental anti-cancer antibody-drug conjugates such as vorsetuzumab mafodotin and SGN-CD19A. In International Nonproprietary Names for MMAF-antibody-conjugates, the name mafodotin refers to MMAF plus its attachment structure to the antibody.

警示圖
危險(xiǎn)性	warning
危險(xiǎn)性警示	Not available
安全聲明	H303+H313+H333
安全防護(hù)	P264+P280+P305+P351+P338+P337+P313
備注	實(shí)驗(yàn)過程中防止吸入、食入，做好安全防護(hù)

CytotoxicPayloadsforAntibody–DrugConjugates,CHAPTER4AuristatinPayloadsforAntibody–DrugConjugates(ADCs).SvetlanaO.Doronina,PeterD.Senter,2019

Pages73-99CytotoxicPayloadsforAntibody–DrugConjugates,SubjectIndex,2019

Pages472-480CytotoxicPayloadsforAntibody–DrugConjugates,Contents,2019

PagesP011-P021CytotoxicPayloadsforAntibody–DrugConjugates,CHAPTER6Colchicine-,Vinblastine-,Taxol-andEribulin-basedPayloadsforAntibody–DrugConjugates(ADCs).ArpitaVelani,SyafiqKay,EarlF.Albone,DavidE.Thurston,2019

Pages117-136Biotherapeutics:RecentDevelopmentsusingChemicalandMolecularBiology,CHAPTER6RecentAdvancesinAntibody–DrugConjugates.EdmundI.Graziani,L.NathanTumey,2013

1.Improved efficacy of alphavbeta3-targeted albumin conjugates by conjugation of a novel auristatin derivative.
Temming K;Meyer DL;Zabinski R;Senter PD;Poelstra K;Molema G;Kok RJ Mol Pharm. 2007 Sep-Oct;4(5):686-94. Epub 2007 Aug 8.
Cellular handling of drug delivery preparations en route to the lysosomal compartment has been extensively studied, but little is known about cellular handling of drugs subsequent to their release from the delivery system. We studied a series of closely related drug targeting conjugates, consisting of albumins equipped with alpha vbeta 3-selective RGD-peptide homing ligands, PEG stealth domains, and either the antitubulin agent monomethyl auristatin E (MMAE) or a new F-variant (MMAF). Since MMAF has a C-terminal charge, this compound is potentially less prone to passive redistribution after its release from the carrier. We demonstrate that RGD-peptide-equipped albumin conjugates with MMAF were indeed more potent than MMAE conjugates, in killing both alpha vbeta 3-positive tumor cells and proliferating endothelial cells. Efficacy increased more in tumor cells than in endothelial cells, suggesting different drug redistribution behavior for the two cell types. Binding affinity and uptake of the conjugate and the cellular handling of released drug contributed to the final efficacy of drug-carrier conjugates, highlighting the importance of all aspects to be carefully considered in the design of targeted drug delivery preparations.

對不起，暫無產(chǎn)品評價(jià)！

MSDS

SDS 1.0 中文

展開

SDS 1.0 英文

展開